Objective: The aim: To pharmacoeconomic analysis of direct medical costs for self-control of diabetes in Ukraine, Moldova and Georgia. Our observational, cross-sectional study aims at finding out the real costs of covering expenses in order to make decisions on the reimbursement of self-control means.
Patients and methods: Materials and methods: 1) International and national clinical guidelines for diabetes; 2) information about the prices of glucometers, test strips from online pharmacy services. Systematization, generalization and pharmacoeconomic analysis of direct medical costs were used in the study.
Results: Results: Based on the generalization of recommendations on the frequency of blood glucose control, 3 scenarios were identified, according to which the costs were calculated: Type 1 diabetes; Type 2 diabetes (insulin therapy); Type 2 diabetes (oral hypoglycemic therapy). The authors conducted pharmacoeconomic analysis of direct medical costs for self-control of DM for PWD in Ukraine, Moldova and Georgia. The study shows that the lowest cost of self-control is provided in Ukraine, in addition, Ukraine has a wider choice of glucometers and test strips. It was revealed that the pharmaceutical markets for glycometers in the three countries depends on the import of equipment.
Conclusion: Conclusions: It is advisable to introduce in Ukraine the reimbursement of self-control devices, namely, glucometers and test strips for all categories of PWD, which will contribute to self-control and, as a result, will be able to prevent the development of complications. Certification of continuous glucose monitoring systems will increase access to new technologies that are already widely used in many countries.
Keywords: Medical direct costs; diabetes mellitus; people with diabetes; self-control.